Registry On Efficacy and Safety Of Rosuvastatin, and Atorvastatin and Simvastatin In Hypercholesterolaemia

AstraZeneca800 enrolled

Overview

The objective of this follow-up retrospective study is to evaluate the long term efficacy and safety of rosuvastatin in reducing lipid parameters in clinical practice.

Study Type

OBSERVATIONAL

Enrollment

800

Conditions

Hypercholesterolaemia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Primary hypercholesterolemia * Subjects from first rosuvastatin Registry study

Locations (1)

Research Site

Singapore, Singapore

Outcomes

Primary Outcomes

Percentage of patients who maintain US NCEP ATP III LDL-C target goals after long-term therapy

Time frame: Up to 8 years

Secondary Outcomes

LDL-cholesterol levels

Time frame: Up to 8 years

HDL-cholesterol levels

Time frame: Up to 8 years

Proportion of patients having raised levels of serum CK or ALT

Time frame: Up to 8 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.